SWK Holdings Corporation with ticker code (SWKH) now have 2 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The target price ranges between 23 and 23 calculating the mean target price we have 23. Now with the previous closing price of 14.8 this now indicates there is a potential upside of 55.4%. There is a 50 day moving average of 14.57 and the 200 day moving average is 13.77. The market capitalisation for the company is $191m. Visit the company website at: http://www.swkhold.com
SWK Holdings Corporation, a specialized finance company, focuses on the healthcare sector. The company operates through two segments, Finance Receivables and Pharmaceutical Development. It provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. The company, through its subsidiary, SWK Advisors LLC, offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. The company also engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Its product pipeline includes Ovarest, an oral leuprolide tablet to treat endometriosis; and Tobrate, an oral tobramycin tablet for the treatment of uncomplicated urinary tract infections. The company was formerly known as Kana Software and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.